Levetiracetam Solution
Product Images NDC 53041-660

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 53041-660). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Guardian Drug Company, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

660lev.jpg (660lev)

This text provides important information from a pharmacist about the storage, dispensing, and warnings regarding a medication called Levetiracetam Oral Solution, USP. It advises storing the medication in a specific temperature range, utilizing a light-resistant container with a child-resistant closure, and keeping it away from children. The text also includes details on the manufacturer, Guardian Drug Company, and the dosage instructions.*

FDA Label Image

Structure-1.jpg (Structure 1)

FDA Label Image

Structure-3.jpg (Structure 3)

This text includes percentages and a mention of a statistically significant difference compared to a placebo in a study involving 1000 mg of a substance. The content seems to be related to research or clinical trial results but lacks specific details to provide a comprehensive description.*

FDA Label Image

Structure-4.jpg (Structure 4)

This is an evaluation of the effectiveness of Levetiracetam compared to a placebo. The study shows that Levetiracetam had a lower response rate (35.2%) compared to placebo. The text also mentions the term "statistically significant" which indicates that there may be a notable difference between the two groups in the study.*

FDA Label Image

Structure-5.jpg (Structure 5)

This is a statistical data related to the effectiveness of Levetiracetam at a dose of 3000 mg/day compared to a placebo in treating a certain condition. The results show that Levetiracetam had a statistically significant effect compared to the placebo group.*

FDA Label Image

Structure-6.jpg (Structure 6)

This text mentions the percentage "19.6%" and the product "Fiacto 50". It also indicates that there is a statistical significance when compared to a placebo. The information provided suggests that Fiacto 50 has a notable effect when compared to a placebo intervention.*

FDA Label Image

Structure-7.jpg (Structure 7)

FDA Label Image

Structure-8.jpg (Structure 8)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.